Eran Broshy

Filings by Eran Broshy span 2 companies, the busiest being Theravance Biopharma, Inc. and Certara, Inc. Between 26 April 2022 and 14 May 2026, the trades on record add up to 12 filings.

On the open market, the record shows 1 purchase worth €2,851 and 3 sales worth €962k. Netting one side against the other leaves €960k of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 4 share grants and 4 option exercises.

The latest filing, published on 15 May 2026, reports an option exercise in Certara, Inc. The latest purchase dates back some time: it was published 1,152 days ago, on 23 August 2023. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.